- Home
- TRIB vs APM Comparison
TRIB vs APM Comparison
Compare TRIB & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRIB
- APM
- Stock Information
- Founded
- TRIB 1992
- APM 2010
- Country
- TRIB Ireland
- APM United Kingdom
- Employees
- TRIB N/A
- APM N/A
- Industry
- TRIB Biotechnology: In Vitro & In Vivo Diagnostic Substances
- APM Biotechnology: Pharmaceutical Preparations
- Sector
- TRIB Health Care
- APM Health Care
- Exchange
- TRIB Nasdaq
- APM Nasdaq
- Market Cap
- TRIB 18.3M
- APM 18.9M
- IPO Year
- TRIB N/A
- APM 2018
- Fundamental
- Price
- TRIB $0.95
- APM $1.28
- Analyst Decision
- TRIB
- APM
- Analyst Count
- TRIB 0
- APM 0
- Target Price
- TRIB N/A
- APM N/A
- AVG Volume (30 Days)
- TRIB 67.0K
- APM 110.5K
- Earning Date
- TRIB 11-14-2025
- APM 12-19-2025
- Dividend Yield
- TRIB N/A
- APM N/A
- EPS Growth
- TRIB N/A
- APM N/A
- EPS
- TRIB N/A
- APM N/A
- Revenue
- TRIB $61,555,000.00
- APM N/A
- Revenue This Year
- TRIB $13.51
- APM N/A
- Revenue Next Year
- TRIB $13.14
- APM N/A
- P/E Ratio
- TRIB N/A
- APM N/A
- Revenue Growth
- TRIB 8.31
- APM N/A
- 52 Week Low
- TRIB $0.48
- APM $0.59
- 52 Week High
- TRIB $3.44
- APM $7.49
- Technical
- Relative Strength Index (RSI)
- TRIB 56.27
- APM 42.80
- Support Level
- TRIB $0.80
- APM $1.22
- Resistance Level
- TRIB $0.94
- APM $1.43
- Average True Range (ATR)
- TRIB 0.08
- APM 0.13
- MACD
- TRIB 0.01
- APM 0.00
- Stochastic Oscillator
- TRIB 72.73
- APM 25.45
About TRIB Trinity Biotech plc
Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has two segments namely the Americas, and the Rest of World - Ireland from which it derives a majority of its revenue from the Americas segment.
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in one segment: research and development. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.